Purity criteria of L-Dopa (L-dihydroxyphenylalanine)
Jouin, J.; Saias, E.
Annales Pharmaceutiques Francaises 30(2): 139-144
1972
ISSN/ISBN: 0003-4509 PMID: 5051261 Document Number: 47124
Document emailed within 1 workday
Related Documents
Borisova, N.V.; Kaplun, A.P.; Bogomolov, O.V.; Grigor'ev, V.B.; Iurasov, V.V.; Nikushkin, E.V.; Kryzhanovskiĭ, G.N.; Shvets, V.I. 1996: Physico-chemical properties of liposome forms of L-3,4-dihydroxyphenylalanine (DOPA) and dopamine Bioorganicheskaia Khimiia 22(10-11): 846-851Valori, C.; Brunori, C.A.; Renzini, V.; Porcellati, C. 1971: Simultaneous fluorimetric determination of noradrenaline, adrenaline, dopamine and dopa (3,4- dihydroxyphenylalanine) in the urine Annali Dell'istituto Superiore di Sanita 7(2): 414-421
Proske, H.; Schachtschabel, D.O.; Plamper, G.; Paul, N.; Pfab, R. 1993: Electron microscopic studies of the effect of x-rays and L-3,4-dihydroxyphenylalanine (L-Dopa)--alone and in combination-- on Harding-Passey melanoma cells in monolayer cell culture Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft . 169(8): 500-507
Tang, G.H.; Zhang, L.; Tang, X.L.; Wang, Y.X.; Yin, D.Z. 2001: Synthesis and determination for enantiomeric purity of 6-fluoro-L-DOPA Yao Xue Xue Bao 36(10): 739-742
Bergonzi, P.; Chiurulla, C.; Gambi, D.; Mennuni, G.; Pinto, F. 1975: L-dopa plus dopa-decarboxylase inhibitor. Sleep organization in Parkinson's syndrome before and after treatment Acta Neurologica Belgica 75(1): 5-10
Hansson, C.; Rorsman, H.; Rosengren, E. 1981: Pronounced formation of 5-OH-dopa at enzymatic oxidation of DOPA in the presence of ascorbic acid Acta Dermato-Venereologica 61(2): 147-148
Bizzarri, B.Mattia.; Tortolini, S.; Rotelli, L.; Botta, G.; Saladino, R. 2015: Current Advances in L-DOPA and DOPA-Peptidomimetics: Chemistry, Applications and Biological Activity Current Medicinal Chemistry 22(36): 4138-4165
Guillard, A. 1972: Treatment of Parkinson syndromes with L-Dopa and the association of L-Dopa and a decarboxylase inhibitor Bruxelles Medical 52(10): 673-680
Riley, P.A. 1999: The great DOPA mystery: the source and significance of DOPA in phase i melanogenesis Cellular and Molecular Biology 45(7): 951-960
Zabel, M. 1979: Ultrastructure of thyroid C cells following long-term administration of 1-DOPA or alpha-methyl-DOPA Acta Medica Polona 20(1): 53-54
Gauthier, G.; de Ajuriaguerra, J.; Geissbuhler, F.; Simona, B.; Constantinidis, J.; Yanniotis, G.; Krassoievitch, M.; Eisenring, J.J.; Tissot, R. 1971: Substitutive therapy in Parkinson's syndromes. L-dopa plus peripheral decarboxylase inhibitor or 3-0-methyl dopa? La Presse Medicale 79(3): 91-92
Vasil'ev, V.N. 1980: Effect of a test with 0.1 g of L-DOPA on the dynamics of urinary excretion of catecholamines and DOPA in schizophrenic patients Voprosy Meditsinskoi Khimii 26(6): 782-786
Routh, J.I.; Bannow, R.E.; Fincham, R.W.; Stoll, J.L. 1971: Excretion of L-dopa and its metabolites in urine of Parkinson's disease patients receiving L-dopa therapy Clinical Chemistry 17(9): 867-871
Blair, M.L.; Reid, I.A.; Ganong, W.F. 1977: Effect of L-dopa on plasma renin activity with and without inhibition of extracerebral dopa decarboxylase in dogs Journal of Pharmacology and Experimental Therapeutics 202(1): 209-215
Muenter, M.D.; Tyce, G.M. 1971: L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects Mayo Clinic Proceedings 46(4): 231-239
Pontiroli, A.E.; Castegnaro, E.; Vettaro, M.P.; Viberti, G.C.; Pozza, G. 1977: Stimulatory effect of the dopa-decarboxylase inhibitor Ro 4-4602 on prolactin release; inhibition by l-dopa, metergoline, methysergide and 2-Br-alpha-ergocryptine Acta Endocrinologica 84(1): 36-44
Indo, T.; Takahashi, A. 1987: Should L-dopa therapy for Parkinson's disease be started early or late? Clinical course of the major tetrad in 122 Parkinsonian patients treated with L-dopa over 14 years Rinsho Shinkeigaku 27(11): 1419-1422
Geissbuhler, F.; Eisenring, J.J.; Friedli, P.; Bartholini, G.; Tissot, R. 1972: Cerebral and peripheral L-dopa uptake in patients with parkinsonian, depressive or manic syndromes administered L-dopa by perfusion combined or not with a decarboxylase inhibitor. Pharmacological effects L'Encephale 61(2): 127-148
Christiani, K.; Möller, W.D. 1973: Drug therapy of Parkinson's syndrome. Clinical long-term study using L-dopa and the drug conbination L-dopa-decarboxylase inhibitor Münchener Medizinische Wochenschrift 115(16): 711-713
Yamamoto, K.; Shirai, T.; Katoh, S.; Yasuda, A.; Kitao, M. 1988: Plasma levels of dihydroxyphenylalanine, dopamine and norepinephrine in the fetoplacental unit and maternal circulation at delivery Nihon Sanka Fujinka Gakkai Zasshi 40(12): 1894-1898